Safety and Immunogenicity of Inactivated Whole Virion COVID-19 Vaccine CoviVac in Clinical Trials in 18–60 and 60+ Age Cohorts

Autor: Ilya V. Gordeychuk, Liubov I. Kozlovskaya, Aleksandra A. Siniugina, Nadezhda V. Yagovkina, Vladimir I. Kuzubov, Konstantin A. Zakharov, Viktor P. Volok, Maria S. Dodina, Larissa V. Gmyl, Natalya A. Korotina, Rostislav D. Theodorovich, Yulia I. Ulitina, Dmitry I. Vovk, Marina V. Alikova, Anna A. Kataeva, Anna V. Kalenskaya, Irina V. Solovjeva, Elena V. Tivanova, Larissa Y. Kondrasheva, Antonina A. Ploskireva, Vasiliy G. Akimkin, Ksenia A. Subbotina, Georgy M. Ignatyev, Anastasia K. Korduban, Elena Y. Shustova, Ekaterina O. Bayurova, Alla S. Zhitkevich, Daria V. Avdoshina, Anastasia N. Piniaeva, Anastasia A. Kovpak, Liliya P. Antonova, Yulia V. Rogova, Anna A. Shishova, Yury Y. Ivin, Svetlana E. Sotskova, Konstantin A. Chernov, Elena G. Ipatova, Ekaterina A. Korduban, Aydar A. Ishmukhametov

Publikováno v: Viruses, Vol 15, Iss 9, p 1828 (2023)

We present the results of a randomized, double-blind, placebo-controlled, multi-center clinical trial phase I/II of the tolerability, safety, and immunogenicity of the inactivated whole virion concentrated purified coronavirus vaccine CoviVac in volu

Externí odkaz: https://doaj.org/article/888b158eaf434d709bf07e578aead9e6

Clinical and morphological features of breast tumors with PIK3CA mutations in Russian patients: Observational study

Autor: Tatyana N. Sokolova, Tatyana I. Solov'eva, Svetlana N. Aleksakhina, Grigorii A. Janus, Alla Goryainova, Mark I. Gluzman, Rashida V. Orlova, Anastasiya I. Stukan, Ruslan A. Zukov, Alena V. Zyuzyukina, Yulia N. Murunova, Aleksandr V. Sultanbaev, Elena N. Vorobeva, Leonid M. Mikhaevich, Victoria N. Pyliv, Anna N. Lysenko, Zarema K. Khachmamuk, Andrey E. Kozlov, Sergey Y. Bakharev, Shahen G. Parsyan, Elena I. Rossokha, Leri D. Osidze, Irina S. Shumskaya, Anna V. Agaeva, Tatiana A. Kasmynina, Veronika V. Klimenko, Kamila T. Akhmetgareeva, Almira A. Vakhitova, Madina D. Chakhkieva, Vadim N. Dmitriev, Yana I. Bakshun, Alexey E. Vasilyev, Dunya D. Gasimly, Nadezhda A. Kravchenko, Dmitriy A. Maksimov, Alfia I. Nesterova, Ineza O. Sharvashidze, Christina H. Gadzaova, Galina G. Rakhmankulova, Zaur M. Khamgokov, Irina K. Amirkhanova, Ludmila V. Bembeeva, Vladimir I. Vladimirov, Oleg L. Petrenko, Natalia G. Ruskova, Ekaterina L. Serikova, Ksenia S. Subbotina, Svetlana A. Tkachenko, Victor L. Chang, Sanal P. Erdniev, Victoria S. Barbara, Anna V. Vasilevskaya, Yulia V. Mikheeva, Nataliya O. Popova, Ekaterina P. Startseva, Anastasia V. Fateeva, Denis Y. Yukalchuk, Anna A. Grechkina, Khedi S. Musaeva, Svetlana V. Odintsova, Alena S. Stel'makh, Petimat I. Khabibulaeva, Alina G. Khlobystina, Kseniya A. Shvaiko, Elena A. Basova, Irina A. Bogomolova, Marina B. Bolieva, Viktor E. Goldberg, Marianna V. Kibisheva, Konstantin V. Menshikov, Dmitrii V. Ryazanov, Mariya L. Stepanova, Yana A. Udalova, Aleksandr V. Shkradyuk, Yana S. Chapko, Anna A. Shchukina, Idris M. Khabriev, Dmitrii V. Kirtbaya, Alexey M. Degtyarev, Aleksandr A. Epkhiev, Yana A. Tyugina, Mirza A. Murachuev, Aleksandr V. Togo, Aglaya G. Ievleva, Evgenii N. Imyanitov

Publikováno v: Современная онкология, Vol 24, Iss 1, Pp 12-23 (2022)

Background. By 2020, breast cancer (BC) has become the most frequent malignancy in the world. The most common type of BC is HR+/HER2-negative cancer,2540% of which harbors PIK3CA mutations that affect the catalytic subunit of the PI3K protein. PIK3CA

Externí odkaz: https://doaj.org/article/ac2dc051d6cd4d1686520ce6a60f66af

Safety and immunogenicity of inactivated whole virion vaccine CoviVac against COVID-19: a multicenter, randomized, double-blind, placebo-controlled phase I/II clinical trial

Autor: Aydar A Ishmukhametov, Aleksandra A Siniugina, Nadezhda V Yagovkina, Vladimir I Kuzubov, Konstantin A Zakharov, Viktor P Volok, Maria S Dodina, Larissa V Gmyl, Natalya A Korotina, Rostislav D Theodorovich, Yulia I Ulitina, Andrey A Tsaan, Tatiana V Pomaskina, Anna V Kalenskaya, Irina V Solovjeva, Elena V Tivanova, Larissa Y Kondrasheva, Antonina A Ploskireva, Vasiliy G Akimkin, Ksenia A Subbotina, Georgy M Ignatyev, Anastasia K Korduban, Elena Y Shustova, Ekaterina O Bayurova, Alla S Kondrashova, Darya V Avdoshina, Anastasia N Piniaeva, Anastasia A Kovpak, Liliya P Antonova, Yulia V Rogova, Anna A Shishova, Yury Y Ivin, Svetlana E Sotskova, Konstantin A Chernov, Elena G Ipatova, Ekaterina A Korduban, Liubov I Kozlovskaya, Ilya V Gordeychuk

We present the results of a randomized, double-blind, placebo-controlled, multi-center clinical trial of the tolerability, safety, and immunogenicity of the inactivated whole virion concentrated purified coronavirus vaccine CoviVac in adult volunteer

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9fa7f5e2e5807fe5981592d7795102a1
https://doi.org/10.1101/2022.02.08.22270658